Morgan Stanley analyst Robert Davies raised the firm’s price target on Fresenius Medical (FMS) to EUR 42 from EUR 39 and keeps an Underweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target raised to EUR 41.50 from EUR 37.30 at JPMorgan
- Fresenius Medical Care Reports Strong Earnings Growth
- Fresenius Medical Care Files 2024 Annual Report with SEC
- Fresenius Medical Care Reports Strong 2024 Financial Results and Raises 2025 Targets
- Cautious Optimism: Hold Rating for Fresenius Medical Care Amid Positive Q3 Performance and 2025 Growth Projections